Importantly, in the context of cancer immunotherapy, IL-2/CD25 FP was found to amplify vaccine-induced, neoantigen-specific CD4+ and CD8+ T cell responses, thereby enhancing antitumor immunity.11 The gene discussed is CD8A; the disease is cancer.